[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1750744B1 - Medikament zur behandlung von pilzinfektionen; insbesondere aspergillose - Google Patents

Medikament zur behandlung von pilzinfektionen; insbesondere aspergillose Download PDF

Info

Publication number
EP1750744B1
EP1750744B1 EP05742910A EP05742910A EP1750744B1 EP 1750744 B1 EP1750744 B1 EP 1750744B1 EP 05742910 A EP05742910 A EP 05742910A EP 05742910 A EP05742910 A EP 05742910A EP 1750744 B1 EP1750744 B1 EP 1750744B1
Authority
EP
European Patent Office
Prior art keywords
ptx3
mice
infection
treatment
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05742910A
Other languages
English (en)
French (fr)
Other versions
EP1750744A1 (de
Inventor
Giovanni c/o Sigma-Tau Industrie Farmaceutiche SALVATORI
Paolo c/o Sigma-Tau Industrie Farmaceutiche CARMINATI
Luigina c/o Università di Perugia ROMANI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority to PL05742910T priority Critical patent/PL1750744T3/pl
Priority to MEP-2008-956A priority patent/ME02743B/me
Priority to SI200530310T priority patent/SI1750744T1/sl
Publication of EP1750744A1 publication Critical patent/EP1750744A1/de
Application granted granted Critical
Publication of EP1750744B1 publication Critical patent/EP1750744B1/de
Priority to CY20081100978T priority patent/CY1108332T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a medicament consisting of a combination of pentraxin PTX3 and an antifungal for the treatment of aspergillosis.
  • IA Invasive aspergilosis
  • BM bone marrow
  • the innate immune system has evolved in a complex, multi-faceted manner to protect lung tissue against infections.
  • the protection of lung tissue is thought to comprise not only a preventive control of microbial proliferation, but also the execution of a balanced inflammatory response sufficient to contain the infection without inducing dangerous degrees of alveolar exudation and infiltration.
  • the molecular components of the alveolar lining have recently been the focus of considerable attention as primary immunomodulators in infections (28, 29).
  • PTX pentraxins
  • PTX3 is a prototype of the long pentraxin that consists in an N-terminal portion coupled to the pentraxin C-terminal domain, the latter being a homologue of the short PTXs (7).
  • PTX3 is secreted by various types of cells, particularly by mononuclear phagocytes, endothelial cells and dendritic cells (DC), in response to the primary inflammatory cytokines in vitro and in vivo (11, 38, 18).
  • PTX3 binds a number of selected microbial agents (e.g. A. fumigatus conidia and P. aeruginosa) and activates various effector pathways of the immune system to combat the infectivity of the pathogen (20).
  • A. fumigatus conidia and P. aeruginosa microbial agents
  • P. aeruginosa microbial agents
  • PTX3 is a pattern recognition receptor (PRR) that plays a non-redundant role in the resistance to selected pathogens (20).
  • PRR pattern recognition receptor
  • the susceptibility of PTX3-deficient mice to A. fumigatus has been associated with unsuccessful organisation of the type I adaptive immune response, but is restored by the exogenous administration of recombinant PTX3 (20).
  • amphotericin B a first-choice drug
  • Various amphotericin B lipid-based formulations have been developed to reduce the toxicity associated with conventional D-AmB (25), as well as with L-AmB (2).
  • the pharmacokinetic profile of L-AmB toxicity is more favourable than that of D-AmB, thus making full-dose therapy possible. Nevertheless, the failure rate is still a matter for concern (1).
  • pentraxin PTX3 exerts a surprising synergistic effect when combined with other antifungal agents, thus permitting the preparation of a drug characterised by suboptimal doses of antifungal.
  • This characteristic proves to be advantageous in terms of the greater manageability of the medicament, in that it is capable of substantially limiting the side effects characteristic of its individual active ingredients.
  • one object of the present invention is a combination of pentraxin PTX3 and an antifungal agent, as well as a pharmaceutical composition containing it and the use of said combination for the preparation of a medicament for the prophylactic or therapeutic treatment of fungal infections, particularly aspergillosis.
  • Pentraxin PTX3 and its various therapeutic uses are described in various patent applications filed in th name of the present applicant.
  • the antifungal agent is amphotericin B, more preferably in the deoxycholate form known on the market under the trade mark Fungizone (Bristol-Myers Squibb) or in the liposomal formulation known on the market under the trade mark AmBisome (GILEAD).
  • the long pentraxin PTX3 and the antifungal will be in the form of a pharmaceutical composition in which the active ingredients are solubilised and/or vehicled by pharmaceutically acceptable excipients and/or diluents.
  • compositions that can be used for long pentraxin PTX3 are also those described in WO 99/32516 .
  • the combination according to the present invention can be administered by the enteral or parenteral routes.
  • the daily dose will depend, according to the judgement of the primary care physician, on the weight, age and general condition of the patient.
  • the fungal infection is invasive aspergillosis (IA).
  • the combination according to the invention has been assessed in the murine bone marrow transplant model which replicates the immunodeficiency observed in the same conditions in man.
  • the mice are submitted to different treatment regimens and assessed for resistance to IA and innate and adaptive immunity parameters.
  • the results have shown that PTX3 induced total resistance to infection and reinfection, that it activated type I protective responses and that it considerably increased the therapeutic efficacy of the antifungal agents when administered in combination.
  • mice Female BALB/c and C3H/HeJ mice aged 8-10 weeks were supplied by Charles River Breeding Laboratories (Calco, Italy). The mice were bred under specific axenic conditions. BM-transplanted mice were housed in small sterile cages (5 animals per cage) and fed with sterile feed and water. All procedures regarding the animals and their care were carried out in conformity with national and international laws and standards. All in-vivo studies were conducted in conformity with the national guidelines and with those of the Committee for the Care and Use of Animals of the University of Perugia.
  • BM-transplant model Bone marrow (BM) cells from BALB/c donor mice were prepared by differential agglutination with soy agglutinin. T-lymphocyte-depleted cells (less than 1% of contaminating T cells as measured by FACS analysis) were injected intravenously (i.v.) at a concentration of ⁇ 4 x 10 6 /mL in recipient C3H/HeJ mice exposed to the lethal dose of 9 Gy (33). Without the BM transplant, the mice died within 14 days. According to previous studies (33), more than 95% of mice survived, which shows a haematopoietic chimerism of the stable donor, as detected by the expression of MHC class I, of the donor type, in cells from the spleen.
  • mice were lightly anaesthetised by means of the inhalation of ethyl ether prior to the instillation of a suspension of 2 x 10 7 conidia/20 ⁇ L saline solution, which was delivered slowly through the nostrils using a micropipette with a sterile disposable tip. This procedure was repeated for 3 consecutive days.
  • the mice surviving the primary intranasal (i.n.) infection were inoculated with 5 x 10 5 of Aspergillus conidia i.v.
  • the fungal load in the lungs, brain and kidneys of the infected mice was quantified by serial plating on Sabouraud dextrose medium and the results (mean ⁇ SE) were expressed as colony forming units (CFU) in samples taken from the organs indicated.
  • CFU colony forming units
  • the fungal growth was also evaluated by chitin analysis (10).
  • the lung was removed and immediately fixed in formalin. Sections (3 to 4 ⁇ m) of tissues embedded in paraffin were stained with the periodic acid Schiff base procedure (13, 20).
  • PTX3 (SIGMA-Tau, Pomezia, Rome, Italy) was purified by immunoaffinity chromatography from the culture supernatants of CHO cells CHO transfected with PTX3 and monitored for the absence of endotoxins (20).
  • PTX3, amphotericin B or AmBisome were administered intraperitoneally (i.p.) or intranasally (i.n.) (PTX3 only) for 5 days before infection with Aspergillus (prophylactic treatment), concomitantly with infection and for 5 days after infection, or for 5 days after the last injection of conidia (therapeutic treatment).
  • PTX3 and the conidia were administered separately.
  • the control animals received only the diluent or sterile saline solution.
  • the phenotype of the various cell types was assessed using murine antibodies against the antigens indicated with rat antimouse antibodies conjugated with FITC from PharMingen (San Diego, Ca). Prior to immunochemical identification, the FcR was saturated by incubation of the cells with 5% normal serum. Histotype antibodies were used as controls. The analysis was done by means of FACScan (Becton Dickinson, Mountain View, Ca). The data obtained were evaluated as percentage of positive cells. The histograms are representative of one of four independent experiments.
  • RNA 5 ⁇ g, extracted from CD4 + T spleen cells using the RNeasy Mini Kit (QIAGEN S.p.A., Milan, Italy) was retrotranscribed with Sensis-cript reverse transcriptase (QIAGEN) according to the manufacturer's indications.
  • the primers for PCR were obtained from Applied Biosystems (Foster City, Ca). The samples were subjected to 40 amplification cycles at 95°C for 15 seconds, and then at 60°C for 1 min using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems).
  • PCR amplification of the eukaryotic 18S rRNA housekeeping gene was done in order to allow normalisation of samples according to the manufacturer's instructions (Applied Biosystems). The controls with water were included in order to ensure specificity. All the data were examined for integrity by analysis of the amplification graph. The data normalised with RNA 18S were expressed as relative mRNA of the cytokines examined ( ⁇ Ct) and compared with those of naive mice (10).
  • cytokines Analysis of cytokines and "spot enzyme-linked, immuno-sorbent" (ELISPOT) analysis.
  • the detection limits of the analyses (pg/ml) were ⁇ 16 for IL-12 p70, ⁇ 32 for TNF- ⁇ , ⁇ 10 for IFN-y and ⁇ 3 for IL-4 and IL-10.
  • ELISPOT analysis was used on purified CD4 + T spleen cells (9, 10). The results were expressed as the mean number of cells producing cytokines ( ⁇ SE) per 10 5 cells, calculated using replicates of the serial cell dilutions.
  • mice were subjected to treatments with different doses of PTX3 administered intranasally or intraperitoneally, before, concomitantly with or after infection.
  • PTX3 levels were high in bronchoalveolar lavage fluids for at least 24 h (from 70 to 25 ng/ml from 2 to 24 h) and that they were higher than those observed in mice with IA one day after infection (from 2 to 15 ng/ml) (20 and unpublished data).
  • the survival parameters and fungal load in the lung and brain were then recorded and analysed in comparison with those obtained in mice treated with different doses of AmBisome or Fungizone. The results showed that PTX3 administered prophylactically (Fig.
  • PTX3 administered after infection increased the survival of the mice only at the higher dose, although at both doses it significantly reduced the fungal load in the lung and at the higher dose it significantly reduced the fungal load in the brain (Fig. 1C). No difference was observed between the two administration routes. Similar results were observed in mice treated with 5 mg/kg of AmBisome, in that all the mice survived the infection when treated before or after infection ( Fig. 1D ). Fungizone did not afford the same level of protection and an increase in survival was observed as well as a decrease in fungal load only at the highest tolerated dose (4 mg/kg) administered after infection ( Fig. 1E ).
  • mice with IA resistance to infection correlates with activation of Th1 cells that produce IFN- ⁇ (12, 13).
  • PTX3 activated Th1 cell reactivity in BM-transplanted mice with IA
  • FACS analysis local cytokine production and the antifungal activity of the effector phagocytes.
  • the quantitative evaluation of blood leukocytes indicated that the absolute number of circulating neutrophils increased significantly following treatment with PTX3 (data not shown). Nevertheless, since levels of neutrophils in the blood do not enable us to predict susceptibility to aspergillosis (5), the cytofluorometric analysis was performed on lung and spleen cells.
  • Figure 5A shows that the treatment with PTX3 substantially increased IL-12 production (approximately 4-fold); however, the production of IL-10 was only halved (as compared to the untreated control), a result suggesting that PTX3 exerts a subtle control over the inflammatory process at the site of infection.
  • PTX3 treatment increased the frequency of CD4 + Th1 cells in the spleen and reduced that of the cells producing IL-4 ( Fig. 5B ), a finding confirmed by evaluation of the mRNA expression levels of cytokines by means of quantitative PCR.
  • Figure 5C shows that both prophylactic and therapeutic treatment with PTX3 significantly increased the expression of IFN-y and reduced that of IL-4.
  • PTX3 greatly reduced the production of TNF- ⁇ in the lungs of mice that received Fungizone, as compared to the levels observed in mice treated with the drug alone; the level of production of TNF- ⁇ as a reaction to AmBisome was lower compared to that induced by treatment with Fungizone and was not modified by treatment in combination with PTX3 ( Fig. 7A ).
  • PTX3 would appear to operate synergistically with AmBisome, more than with Fungizone, in reducing the pulmonary inflammatory response and in promoting Th1 antifungal reactivity.
  • PTX3 induced a curative response in mice with IA with minimal disease.
  • PTX3 was effective when administered prophylactically and that it shows no direct activity on fungal cells, it would appear that the beneficial effect depends on its ability to activate a Thl-dependent protective resistance.
  • PTX3 activates at least two effector pathways against the pathogenic infectivity, namely, the classic complement activation pathway, in the C1q binding (35), and the promotion of phagocytosis through interaction with one or more as yet unidentified cell receptors (20). It is likely that internalisation of the conidia by the resident mononuclear cells may serve to limit the fungal infectivity and permit recovery of the myeloid and lymphoid cells in the lung. PTX3, however, also activates DCs through the production of IL-12 and expression of co-stimulatory molecules in response to Aspergillus conidia (20). Thus, the rapid onset of the production of PTX3 in DCs through members of the Toll-like receptor (TLR) family (18) implies a direct role of PTX3 in the amplification of innate resistance and in orienting adaptive immunity.
  • TLR Toll-like receptor
  • IL-12 The production of IL-12 was increased and that of IL-10 reduced in the lungs of infected mice treated with PTX3, a result that indicates an inflammatory response. Nevertheless, the production of TNF- ⁇ was not increased by treatment with PTX3, which suggests that PTX3, like a number of collectins, may act as a fine regulator of the equilibrium between pro- and anti-inflammatory stimuli (42, 48).
  • the therapeutic efficacy of AmBisome and Fungizone was evaluated in the BM transplant infection model which parallels the profound immunopathology witnessed in .
  • BM transplant recipients where the susceptibility to invasive fungal infections is causally related to the development or otherwise of protective Th responses (15, 33).
  • AmBisome displayed superior activity as compared to Fungizone in mice with IA after BM transplant.
  • Both daily prophylactic and therapeutic treatments with 5 mg/kg AmBisome cured the mice of infection and reduced the fungal load in the lung.
  • D-AmB we observed only a slightly increased resistance to infection at the highest tolerated doses (e.g. 4 mg/kg) administered after infection.
  • the combined treatment with PTX3 greatly reduced the production of TNF- ⁇ induced by the treatment with Fungizone, whereas it con-comitantly increased the therapeutic efficacy of the drug, as shown by the increased survival and reduced fungal load in the mice treated with the combination of PTX3 and D-AmB following infection.
  • Combined therapy with PTX3 also increased the efficacy of the suboptimal dose of AmBisome without affecting TNF- ⁇ production levels, as compared to those observed with each single treatment. Therefore, the activity of PTX3 in coadministration with antifungal agents may depend on an effect that goes beyond the lowering of TNF- ⁇ production.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Claims (8)

  1. Kombination von Pentraxin PTX3 und einem antifungalen Wirkstoff.
  2. Kombination gemäß Anspruch 1, in welcher der antifungale Wirkstoff Amphotericin B ist.
  3. Kombination gemäß Anspruch 2, in welcher Amphotericin B in der Deoxycholat-Form oder in einer liposomalen Formulierung vorliegt.
  4. Pharmazeutische Zusammensetzung bestehend aus einer Kombination gemäß irgendeinem der Ansprüche 1-3.
  5. Zusammensetzung gemäß Anspruch 4, enthaltend suboptimale Dosen des antifungalen Wirkstoffs.
  6. Verwendung der Kombination gemäß irgendeinem der Ansprüche 1-3 für die Herstellung eines Arzneimittels für die prophylaktische oder therapeutische Behandlung von Pilzinfektionen.
  7. Verwendung gemäß Anspruch 6, in welcher das Arzneimittel suboptimale Dosen des antifungalen Wirkstoffs enthält.
  8. Verwendung gemäß den Ansprüchen 6 und 7, in welcher die Pilzinfektion Lungenaspergillose ist.
EP05742910A 2004-05-07 2005-04-28 Medikament zur behandlung von pilzinfektionen; insbesondere aspergillose Active EP1750744B1 (de)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PL05742910T PL1750744T3 (pl) 2004-05-07 2005-04-28 Lek do leczenia infekcji grzybiczych, w szczególności aspergilozy
MEP-2008-956A ME02743B (me) 2004-05-07 2005-04-28 Lek za lečenje gljivičnih infekcija, naročito aspergiloze
SI200530310T SI1750744T1 (sl) 2004-05-07 2005-04-28 Zdravilo za zdravljenje gliviäśnih infekcij, zlasti aspergiloze
CY20081100978T CY1108332T1 (el) 2004-05-07 2008-09-11 Φαρμακο για τη θεραπεια μυκητιακων λοιμωξεων, ειδικοτερα της ασπεργιλλωσης

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000223A ITRM20040223A1 (it) 2004-05-07 2004-05-07 Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
PCT/IT2005/000247 WO2005107791A1 (en) 2004-05-07 2005-04-28 Medicament for the treatment of fungal infections, particularly aspergillosis

Publications (2)

Publication Number Publication Date
EP1750744A1 EP1750744A1 (de) 2007-02-14
EP1750744B1 true EP1750744B1 (de) 2008-06-11

Family

ID=34968212

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05742910A Active EP1750744B1 (de) 2004-05-07 2005-04-28 Medikament zur behandlung von pilzinfektionen; insbesondere aspergillose

Country Status (25)

Country Link
US (2) US8778389B2 (de)
EP (1) EP1750744B1 (de)
JP (1) JP5574565B2 (de)
KR (1) KR101192611B1 (de)
CN (1) CN1950104B (de)
AR (1) AR048775A1 (de)
AT (1) ATE397937T1 (de)
AU (1) AU2005239913B2 (de)
BR (1) BRPI0510718A (de)
CA (1) CA2563400C (de)
CY (1) CY1108332T1 (de)
DE (1) DE602005007485D1 (de)
DK (1) DK1750744T3 (de)
ES (1) ES2306145T3 (de)
HK (1) HK1103961A1 (de)
HR (1) HRP20080413T3 (de)
IT (1) ITRM20040223A1 (de)
ME (1) ME02743B (de)
MX (1) MXPA06012889A (de)
PL (1) PL1750744T3 (de)
PT (1) PT1750744E (de)
RS (1) RS50591B (de)
SI (1) SI1750744T1 (de)
TW (1) TWI393569B (de)
WO (1) WO2005107791A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20040489A1 (it) * 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1832295A1 (de) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Verwendung von PTX3 zur Behandlung viraler Erkrankungen
ITMI20062448A1 (it) * 2006-12-19 2008-06-20 Univ Degli Studi Modena E Reggio Emilia Metodo per la diagnosi e/o il monitoraggio dell¿ aspergillosi invasiva
US8838152B2 (en) 2007-11-30 2014-09-16 Microsoft Corporation Modifying mobile device operation using proximity relationships
CN101280326B (zh) * 2008-05-14 2011-07-06 中国科学院微生物研究所 一种抑制烟曲霉活性的化合物制备方法及其应用
US20150299277A1 (en) * 2012-06-22 2015-10-22 The University Of Tokyo Agent for treating or preventing systemic inflammatory response syndrome
EP3803396B1 (de) * 2018-06-01 2023-03-01 B.R.A.H.M.S GmbH Biomarker zur diagnose von invasiven pilzinfektionen
EP3669885A1 (de) * 2018-12-20 2020-06-24 Humanitas Mirasole S.p.A. Verwendung von sap zur behandlung von eurotiomycetes-pilzinfektionen
CN113952401B (zh) * 2021-12-15 2022-10-25 河北农业大学 一种用于防治畜禽曲霉菌感染的中药及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5059591B1 (en) * 1983-05-26 2000-04-25 Liposome Co Inc Drug preparations of reduced toxicity
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
JP2001183375A (ja) 1999-12-27 2001-07-06 Tosoh Corp 酵素標識抗体
WO2005026195A1 (en) * 2003-09-12 2005-03-24 Board Of Regents, The University Of Texas System Biopanning as an approach to study the pathogenesis of and produce novel treatment modalities for invasive aspergillosis
EP1730095A4 (de) * 2004-03-29 2008-04-02 Univ Mississippi Neue, gegen pilze wirkende cyclopentendionverbindungen und verfahren zu deren anwendung
ITRM20040489A1 (it) 2004-10-08 2005-01-08 Sigma Tau Ind Farmaceuti Pentraxina lunga ptx3 deglicosilata o desialidata.
EP1832295A1 (de) 2006-03-10 2007-09-12 Tecnogen S.P.A. Verwendung von PTX3 zur Behandlung viraler Erkrankungen
US8337828B2 (en) 2006-05-02 2012-12-25 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of thymosin alpha 1, alone or in combination with PTX3 or ganciclovir, for the treatment of cytomegalovirus infection

Also Published As

Publication number Publication date
DE602005007485D1 (de) 2008-07-24
JP2007536380A (ja) 2007-12-13
ITRM20040223A1 (it) 2004-08-07
DK1750744T3 (da) 2008-09-29
EP1750744A1 (de) 2007-02-14
CN1950104B (zh) 2010-11-10
ME02743B (me) 2010-05-07
CA2563400A1 (en) 2005-11-17
US8778389B2 (en) 2014-07-15
CA2563400C (en) 2013-07-30
PL1750744T3 (pl) 2008-11-28
HK1103961A1 (en) 2008-01-04
ES2306145T3 (es) 2008-11-01
US20080026997A1 (en) 2008-01-31
KR20070007375A (ko) 2007-01-15
JP5574565B2 (ja) 2014-08-20
US20140296135A1 (en) 2014-10-02
TW200602075A (en) 2006-01-16
WO2005107791A1 (en) 2005-11-17
HRP20080413T3 (en) 2008-10-31
CY1108332T1 (el) 2014-02-12
AR048775A1 (es) 2006-05-24
BRPI0510718A (pt) 2007-11-20
RS50591B (sr) 2010-05-07
AU2005239913B2 (en) 2011-08-18
KR101192611B1 (ko) 2012-10-18
PT1750744E (pt) 2008-08-14
CN1950104A (zh) 2007-04-18
TWI393569B (zh) 2013-04-21
ATE397937T1 (de) 2008-07-15
AU2005239913A1 (en) 2005-11-17
SI1750744T1 (sl) 2008-10-31
MXPA06012889A (es) 2007-02-15

Similar Documents

Publication Publication Date Title
US20140296135A1 (en) Medicament for the treatment of fungal infections particularly aspergillosis
Gaziano et al. Anti-Aspergillus fumigatus efficacy of pentraxin 3 alone and in combination with antifungals
Ko et al. Mesenchymal stem and stromal cells harness macrophage-derived amphiregulin to maintain tissue homeostasis
Romani et al. Thymosin α 1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling
Bourgeois et al. Fungal pathogens—a sweet and sour treat for toll-like receptors
Tesar et al. The role of hyaluronan degradation products as innate alloimmune agonists
Alti et al. Emergence of leptin in infection and immunity: scope and challenges in vaccines formulation
Luo et al. LL37 inhibits Aspergillus fumigatus infection via directly binding to the fungus and preventing excessive inflammation
EP2525814A2 (de) Verfahren zur behandlung oder verhinderung von parodontitis und mit parodontitis assoziierten erkrankungen
Lai et al. M2C polarization by baicalin enhances efferocytosis via upregulation of MERTK receptor
Mouradian et al. Superoxide dismutase 3 R213G single-nucleotide polymorphism blocks murine bleomycin-induced fibrosis and promotes resolution of inflammation
Chen et al. Propofol inhibits endogenous formyl peptide-induced neutrophil activation and alleviates lung injury
Zhang et al. PD-1 deficiency promotes macrophage activation and T-helper cell type 1/T-helper cell type 17 response in pneumocystis pneumonia
US20230173031A1 (en) Thymosin alpha 1 for use in treatment of cystic fibrosis
Iraz et al. Protective effect of\beta-glucan on acute lung injury induced bylipopolysaccharide in rats
Song et al. Contribution of Nlrp3 inflammasome activation mediated by suilysin to streptococcal toxic shock-like syndrome
KR20200126341A (ko) 분리된 미토콘드리아를 유효성분으로 포함하는 패혈증 또는 전신성 염증 반응 증후군 치료용 약학 조성물
Deng et al. Low-dose 5-fluorouracil ameliorates Th2 responses through the induction of apoptotic cell death of lung monocyte-derived dendritic cells in asthma
Quagliata et al. Therapeutic applications of thymosin peptides: a patent landscape 2018-present
Li et al. BPOZ-2 is a negative regulator of the NLPR3 inflammasome contributing to SARS-CoV-2-induced hyperinflammation
Dybvig et al. Biological roles of host defense peptides: lessons from transgenic animals and bioengineered tissues
US20220143159A1 (en) Cystatin C and Cystatin 9 to Treat Inflammation Caused by Bacteria
Li et al. ATF3 deficiency promotes alveolar macrophage pyroptosis in sepsis-induced acute lung injury
JP2023515502A (ja) Ｃｏｖｉｄ－１９を治療するための早期アポトーシス細胞の使用
Tang The role of endoplasmic reticulum stress and inflammasome activation in inflammatory disease: identifying therapeutic targets in cystic fibrosis and haematological malignancies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

17Q First examination report despatched

Effective date: 20070222

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CARMINATI, PAOLOC/O SIGMA-TAU INDUSTRIE FARMACEUTI

Inventor name: ROMANI, LUIGINA,C/O UNIVERSITA DI PERUGIA

Inventor name: SALVATORI, GIOVANNIC/O SIGMA-TAU INDUSTRIE FARMACE

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REF Corresponds to:

Ref document number: 602005007485

Country of ref document: DE

Date of ref document: 20080724

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ROSENICH PAUL; GISLER CHRISTIAN PATENTBUERO PAUL R

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20080805

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20080413

Country of ref document: HR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20080402389

Country of ref document: GR

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20080413

Country of ref document: HR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2306145

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E003779

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20090312

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20080413

Country of ref document: HR

Payment date: 20160407

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LT

Payment date: 20160331

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20160405

Year of fee payment: 12

Ref country code: MC

Payment date: 20160404

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: EE

Payment date: 20160405

Year of fee payment: 12

Ref country code: SI

Payment date: 20160331

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E002096

Country of ref document: EE

Effective date: 20170430

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20080413

Country of ref document: HR

Effective date: 20170428

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20170428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170502

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170430

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170428

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170429

REG Reference to a national code

Ref country code: SI

Ref legal event code: KO00

Effective date: 20180111

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20180426

Year of fee payment: 14

Ref country code: LU

Payment date: 20180427

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CZ

Payment date: 20180410

Year of fee payment: 14

Ref country code: FI

Payment date: 20180427

Year of fee payment: 14

Ref country code: PT

Payment date: 20180403

Year of fee payment: 14

Ref country code: DK

Payment date: 20180426

Year of fee payment: 14

Ref country code: SK

Payment date: 20180404

Year of fee payment: 14

Ref country code: CH

Payment date: 20180502

Year of fee payment: 14

Ref country code: IE

Payment date: 20180427

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20180419

Year of fee payment: 14

Ref country code: TR

Payment date: 20180409

Year of fee payment: 14

Ref country code: AT

Payment date: 20180405

Year of fee payment: 14

Ref country code: BE

Payment date: 20180427

Year of fee payment: 14

Ref country code: RO

Payment date: 20180403

Year of fee payment: 14

Ref country code: BG

Payment date: 20180419

Year of fee payment: 14

Ref country code: GR

Payment date: 20180427

Year of fee payment: 14

Ref country code: IS

Payment date: 20180403

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20180427

Year of fee payment: 14

Ref country code: HU

Payment date: 20180410

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20190429

Year of fee payment: 15

Ref country code: ES

Payment date: 20190521

Year of fee payment: 15

Ref country code: DE

Payment date: 20190521

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20190429

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20190521

Year of fee payment: 15

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

Effective date: 20190430

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20190501

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 397937

Country of ref document: AT

Kind code of ref document: T

Effective date: 20190428

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 4165

Country of ref document: SK

Effective date: 20190428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190501

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191031

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190429

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191028

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191101

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20191105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005007485

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201103

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200430

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20210906

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200428

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190428